ENX-205

A unique 5-HT1A/5-HT2A receptor agonist and D2/D3 antagonist in development for posttraumatic stress disorder (PTSD) and other mood disorders

Posttraumatic stress disorder has varying presentations, but a common feature is dysfunctional serotonergic and dopaminergic neurotransmission, leading to deficits in emotion, fear processing, and cognition.1–3 Restoring balance in serotonin and dopamine neurotransmission may remedy these deficiencies and alleviate a wide range of symptoms.1–3

ENX-205 is a unique 5-HT1A /5-HT2A receptor agonist and D2/D3 receptor antagonist in development for PTSD and other mood disorders. ENX-205 has an excellent pharmacokinetic profile that supports once-daily dosing.4

Through this unprecedented pharmacology, ENX-205 offers the potential to also address a variety of stress-related disorders as well as mood disorders. Extensive profiling is underway to prioritize additional clinical indications for ENX-205.4

Read more about dopamine modulation
Although PTSD affects 5% of the US adult population each year,5 there are few effective treatment options – simultaneously targeting serotonin and dopamine signaling may improve symptom control
Read more about dopamine modulation

+ References and Abbreviations

5-HT1A, serotonin receptor 1A; 5-HT2A, serotonin receptor 2A; D2, dopamine receptor 2; D3, dopamine receptor 3.

1. Sherin JE & Nemeroff CB. Dialogues Clin Neurosci. 2011;13(3):263-278.
2. Lin CC & Liu YP. Pharmaceuticals (Basel). 2022;15(7):788.
3. Al Jowf GI, et al. Int J Mol Sci. 2023;24(6):5238.
4. Engrail Therapeutics. Data on file.
5. U.S. Department of Veteran Affairs. PTSD: National Center for PTSD. Accessed August 5, 2024. https://www.ptsd.va.gov/understand/common/common_adults.asp

T H E R A P E U T I C S

© 2024 Engrail Therapeutics. All rights reserved.